Topics

Fish Oil Flop; Women Leading; MitraClip Expansion Trial

09:00 EST 14 Jan 2020 | MedPageToday

]]>(MedPage Today) -- Fish oil pill Epanova's cardiovascular outcomes trial, STRENGTH, is being abandoned due to lack of efficacy in a mixed dyslipidemia population at high cardiovascular risk, AstraZeneca announced. Some pounced on the news as proof...

Original Article: Fish Oil Flop; Women Leading; MitraClip Expansion Trial

NEXT ARTICLE

More From BioPortfolio on "Fish Oil Flop; Women Leading; MitraClip Expansion Trial"

Quick Search

Relevant Topics

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...